- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07946367
Dual-targeting of B & T Cell Pathways Evaluation Trial (DUET)
Evaluation of Safety, Treatment Response and Biological Effects of DFI205 in Systemic Autoimmune Rheumatic Diseases (SARDs); a Phase 1/2a First-in-Human (FIH) Study
This is a first-in-human study of DFI205, an investigational bispecific antibody that binds CD20 and CD40, with the goal of targeting both B- and T-cell function in adults with active systemic autoimmune rheumatic diseases (SARDs) despite standard therapy. In Phase 1, participants with RA, SLE, SSc or IIM will receive a single dose at increasing dose levels to establish safety and initial treatment response. The selected dose will be carried forward into Phase 2a, where participants will receive monthly doses to assess safety and treatment response.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Bernhard Remes
- Número de teléfono: 0049641944360
- Correo electrónico: info@diabetesfree.com
Ubicaciones de estudio
-
-
-
Erlangen, Alemania, 91054
- Reclutamiento
- Universitaetsklinikum Erlangen AöR
-
Contacto:
- Georg Schett
- Número de teléfono: 00499131-85-32093
- Correo electrónico: Studienambulanz.M3@uk-erlangen.de
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Male and female participants, age 18 years and older.
- Able to understand and comply with all scheduled visits, treatment plans, laboratory tests, and other procedures of the study protocol including ability to provide written informed consent.
- Maintaining a stable, qualifying, standard of care regimen for ≥4 weeks prior to screening as treatment for a qualifying primary diagnosis (RA, SLE, SSc, IIM including the disease-specific criteria listed below):
- Rheumatoid Arthritis (RA) participants must have, 1) positivity of anti-citrullinated protein antibody (ACPA) and/or rheumatoid factor (RF); 2) moderate to highly active disease despite treatment with at least 2 lines of standard therapy; 3) disease duration ≥ 6 months; secondary Sjögren's disease diagnosis is acceptable as long as other criteria are met.
- Systemic Lupus Erythematosus (SLE) participants must have, 1) positivity of anti-nuclear-antibodies (ANA) and/or anti-dsDNA and/or anti-histone and/or anti-nucleosome and/or anti-Sm antibodies; 2) active disease despite treatment with at least 2 lines of standard therapy; 3) disease duration ≥ 6 months.
- Systemic Sclerosis (SSc) participants must have, 1) positivity for at least one SSc-associated autoantibody; 2) mRSS score >10 units or interstitial lung disease (ILD) including clinically relevant pulmonary involvement despite treatment with at least 2 lines of standard therapy; 3) disease duration ≤ 5 years (from onset of first non-Raynaud manifestation); 4) not eligible for or declining autologous hematopoietic stem-cell transplantation
- Idiopathic Inflammatory Myopathies (IIM) participants must have, 1) positivity for at least one myositis-specific antibody; 2) active myositis or presence of ILD defined by clinically relevant pulmonary involvement despite treatment with at least 2 lines of standard therapy; 3) disease duration ≥ 6 months
Exclusion Criteria:
- Diagnosis of a non-rheumatic autoimmune disease requiring therapeutic or investigational immune therapy or modulation (e.g., neuropathy requiring IVIg, Multiple Sclerosis). Milder autoimmune conditions requiring replacement or exocrine functional therapies are acceptable (e.g., Type 1 diabetes, Celiac Disease, Autoimmune Thyroid Disease if on stable treatment for at least 6 months).
- History of any pre-existing liver disease, including cirrhosis, acute liver disease, or chronic liver disease (unless considered stable for >6 months and required screening laboratory tests meet criteria).
- Severe unresolved cardiac disease.
- Estimated glomerular filtration rate (GFR) <30 mL/min/1.73 m2.
- Presence or history of active infections, including hepatitis B, hepatitis C, human immunodeficiency virus (HIV), Human T-lymphotropic virus (HTLV) or tuberculosis. Participants with laboratory evidence of active infection are excluded even in the absence of clinical evidence of active infection. Participants with mild skin and nail fungal infections are not excluded.
- Acute infection requiring systemic therapy or hospitalization within 30 days before screening.
- Invasive aspergillus, histoplasmosis, or coccidioidomycosis infection within one year prior to enrollment.
- Any history of malignancy in the 5 years before screening except for completely resected squamous or basal cell carcinoma of the skin.
- Primary or secondary immunodeficiency, including hypogammaglobulinemia.
- History or evidence of progressive multifocal leukoencephalopathy (PML) or other demyelinating disorders.
- Allergies to humanized monoclonal antibodies or severe post-treatment hypersensitivity reactions other than localized injection site reaction, to any biological molecule.
- Systemic corticosteroid therapy or adrenocorticotropic hormone (ACTH) use within 30 days prior to screening and within entire duration of screening period prior to beginning of study treatment, unless prescribed as background therapy.
- Intolerance of or contraindication to oral or IV corticosteroids.
- Treatment with other biologic or non-biologic immunosuppressant agents (e.g., anti-CD20 therapies, TNF inhibitors, azathioprine, cyclosporine, methotrexate, or mycophenolate) within 6 months prior to screening, unless prescribed as background therapy.
- The participant has taken another investigational drug within 3 months or 5-half-lives before the screening visit, whichever is longer, or any investigational drug that has depleted a cell type or line without recovery.
- Previous treatment with anti-CD19 agents, anti-CD38 agents, bispecific anti-CD19/CD3 T cell engaging therapies, adoptive T cell therapy or any prior gene therapy product.
- Received any form of stem cell transplant.
- Administration of live attenuated vaccine(s) within 12 weeks prior to and 12 weeks after the completion of DFI205 administration or any planned receipt during the study that cannot be delayed. Vaccinations should be up-to-date as per local clinical practice.
- Plasmapheresis within 3 months prior to first dose of DFI205
- Positive pregnancy test, presently breast-feeding, (female participants) or unwillingness to use highly effective contraceptive measures for the duration of the study and 6 months after discontinuation.
- Any condition, including the presence of relevant abnormalities in vital parameters or laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Phase 1 Single Ascending Dose Escalation
Intravenous (IV) infusion of DFI205 at ascending dose levels. |
A bispecific monoclonal antibody that binds to both CD20 and CD40 receptors on cells. |
|
Experimental: Phase 2a Multi-Dose
DFI205 monthly IV infusions at the recommended Phase 2 dose |
A bispecific monoclonal antibody that binds to both CD20 and CD40 receptors on cells. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
To evaluate the initial safety and tolerability of DFI205 in adults with SARDs
Periodo de tiempo: Up to 1 year post-dosing
|
Numbers and types of all adverse events (AEs) and serious adverse events (SAEs) |
Up to 1 year post-dosing
|
|
To monitor immune reconstitution after completion of dosing with DFI205
Periodo de tiempo: Up to 1 year post-dosing
|
Time to normalized peripheral blood B cell counts compared to baseline. |
Up to 1 year post-dosing
|
|
To monitor immune response to DFI205
Periodo de tiempo: Up to 1 year post-dosing
|
Number of participants with anti-drug antibody development. |
Up to 1 year post-dosing
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
To evaluate the ability of DFI205 to induce an objective response in adults with RA
Periodo de tiempo: 24 weeks post-dosing
|
Overall Response Rate (ORR) measured by proportion of participants achieving either low-disease activity (DAS28-CRP ≤ 3.2, DAS28-ESR ≤3.2, SDAI≤11, CDAI≤10) or remission criteria (DAS28-CRP < 2.6, DAS28-ESR <2.6, SDAI ≤3.3, CDAI ≤ 2.8,Boolean 2.0 remission criteria) combined |
24 weeks post-dosing
|
|
To evaluate the ability of DFI205 to induce an objective response in adults with SLE
Periodo de tiempo: 24 weeks post-dosing
|
Overall Response Rate (ORR) measured by fulfillment of DORIS remission criteria |
24 weeks post-dosing
|
|
To evaluate the ability of DFI205 to induce an objective response in adults with SSc
Periodo de tiempo: 24 weeks post-dosing
|
Overall Response Rate (ORR) measured by proportion of participants achieving either modified Rodnan Skin Score (mRSS) decrease of >5 points and ≥ 25% decrease from baseline or no progression of interstitial lung disease (ILD progression defined as FVC decline >10%, or 5-10% plus worsening respiratory symptoms or HRCT progression) combined |
24 weeks post-dosing
|
|
To evaluate the ability of DFI205 to induce an objective response in adults with IIM
Periodo de tiempo: 24 weeks post-dosing
|
Overall Response Rate (ORR) measured by achievement of major response (ACR/EULAR 2016 Myositis Response Criteria Total Improvement Score ≥ 60) |
24 weeks post-dosing
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
To evaluate the ability of DFI205 to reduce disease activity in adults with RA
Periodo de tiempo: 24 weeks post-dosing
|
Change in tender joint count (TJC28) compared to baseline |
24 weeks post-dosing
|
|
To evaluate the ability of DFI205 to reduce disease activity in adults with RA
Periodo de tiempo: 24 weeks post-dosing
|
Change in swollen joint count (SJC28) compared to baseline |
24 weeks post-dosing
|
|
To evaluate the ability of DFI205 to reduce disease activity in adults with SLE
Periodo de tiempo: 24 weeks post-dosing
|
Change in British Isles Lupus Assessment Group (BILAG-2004) score compared to baseline |
24 weeks post-dosing
|
|
To evaluate the ability of DFI205 to reduce disease activity in adults with SSc
Periodo de tiempo: 24 weeks post-dosing
|
Change in mRSS (0=no thickening, 3=severe thickening) compared to baseline |
24 weeks post-dosing
|
|
To evaluate the ability of DFI205 to reduce disease activity in adults with IIM
Periodo de tiempo: 24 weeks post-dosing
|
Change in creatine phosphokinase (CPK) compared to baseline |
24 weeks post-dosing
|
|
To evaluate the ability of DFI205 to reduce disease activity in adults with IIM
Periodo de tiempo: 24 weeks post-dosing
|
Change in muscle strength (MMT8 score) compared to baseline |
24 weeks post-dosing
|
|
To evaluate change in erythrocyte sedimentation rate (ESR) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
Periodo de tiempo: Up to 1 year post-dosing
|
Up to 1 year post-dosing
|
|
|
To evaluate change in C-reactive protein (CRP) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
Periodo de tiempo: Up to 1 year post-dosing
|
Up to 1 year post-dosing
|
|
|
To evaluate change in interleukin-6 (IL-6) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
Periodo de tiempo: Up to 1 year post-dosing
|
Up to 1 year post-dosing
|
|
|
To evaluate change in tumor necrosis factor-alpha (TNF-α) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
Periodo de tiempo: Up to 1 year post-dosing
|
Up to 1 year post-dosing
|
|
|
To investigate the pharmacokinetics of DFI205
Periodo de tiempo: Up to 1 year post-dosing
|
Blood samples will be collected to quantitate serum concentrations of DFI205 |
Up to 1 year post-dosing
|
|
To investigate the pharmacodynamics of DFI205 in blood
Periodo de tiempo: Up to 1 year post-dosing
|
Proportions of immune cell subsets in blood by FACS analysis over the course of the study. |
Up to 1 year post-dosing
|
|
To investigate the secondary lymphoid system pharmacodynamics of DFI205
Periodo de tiempo: Up to 1 year post-dosing
|
Proportions of disease-specific lymph node cell populations over the course of the study. |
Up to 1 year post-dosing
|
|
To investigate soluble CD40 pharmacodynamics of DFI205
Periodo de tiempo: Up to 1 year post-dosing
|
Soluble CD40 receptor/ligand blood concentrations over the course of the study treatments. |
Up to 1 year post-dosing
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Georg Schett, M.D., University of Erlangen-Nürnberg
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades musculoesqueléticas
- Enfermedades del Sistema Nervioso
- Enfermedades Musculares
- Enfermedades Neuromusculares
- Artritis
- Enfermedades Articulares
- Enfermedades reumáticas
- Enfermedades del tejido conectivo
- Enfermedades autoinmunes
- Enfermedades del sistema inmunológico
- Enfermedades de la piel
- Enfermedades de la piel y del tejido conectivo
- Lupus Eritematoso Sistémico
- Esclerodermia Sistémica
- Artritis Reumatoide
- Miositis
Otros números de identificación del estudio
- 2026TXSARD01
- 2026-526672-24-00 (Ctis)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .